Costs and benefits of routine follow-up after curative treatment for endometrial cancer

CMAJ. Canadian Medical Association Journal

Volumn 157, Issue 7, 1997, Pages 879-886

  Agboola, Olu O ^a,d   Grunfeld, Eva ^b   Coyle, Douglas ^c   Perry, Gad A ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Institut national du cancer du Canada   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANCER RECURRENCE; CANCER SURVIVAL; COST BENEFIT ANALYSIS; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PAPANICOLAOU TEST;

EID: 0030772942     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Dewar J. Follow up in breast cancer: a suitable case for reappraisal [editorial]. BMJ 1995;310:685-6.
2. Loprinzi C. It is now the age to define the appropriate follow-up of primary breast cancer patients. J Clin Oncol 1994;12:881-3.
3. Loprinzi C. Follow-up testing for curatively treated cancer survivors. JAMA 1995;273:1877-8.
4. Schapira D, Urban N. A minimalist policy for breast cancer surveillance. JAMA 1991;265:380-2.
5. Grunfeld E, Mant D, Vessey MP, Yudkin P. Evaluating primary care follow-up of breast cancer: methods and preliminary results of three studies. Ann Oncol 1995;6:S47-S52.
6. Richert-Boe KE. Heterogeneity of cancer surveillance practices among medical oncologists in Washington and Oregon. Cancer 1995;75:2605-12.
7. Loomer L, Brockschmidt JK, Muss HB, Saylor G. Postoperative follow-up of patients with early breast cancer. Cancer 1991;67:55-60.
8. Schapira DV. Breast cancer surveillance - a cost-effective strategy. Breast Cancer Res Treat 1993;25:107-11.
9. Mapelli V, Dirindin N, Grilli R. Economic evaluation of diagnostic follow-up after primary treatment for breast cancer. Ann Oncol 1995;6:S61-S4.
10. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-26.
11. Virgo KS, Vernava AM, Longo WE, McKirgan LW, Johnson FE. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995;273:1837-41.
12. Scanlon EF, Oviedo M, Cunningham MP, Caprini JA, Khandekar JD, Cohen E, et al. Preoperative and follow-up procedures on patients with breast cancer. Cancer 1980;46:977-9.
13. Winchester DP, Sener SF, Khandekar JD, Oviedo MA, Cunningham MP, Caprini JA, Burkitt FE, et al. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 1979;43:956-60.
14. Broyn T, Froyen J. Evaluation of routine follow-up after surgery for breast carcinoma. Acta Chir Scand 1982;148:401-4.
15. Holli K, Hakama M. Effectiveness of routine and spontaneous follow-up visits for breast cancer. Eur J Cancer Clin Oncol 1989;25:251-4.
16. Dewar JA, Kerr GR. Value of routine follow-up of women treated for early carcinoma of the breast. BMJ 1985;291:1464-7.
17. Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703-5.
18. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 1994;271:1593-7.
19. GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 1994;271:1587-92.
20. Boring, CC, Squires TS, Tong T, Montgomery S. Cancer statistics. CA Cancer J Clin 1994;44:7-26.
21. National Cancer Institute of Canada. Canadian cancer statistics 1995. Toronto: The Institute; 1995. p. 7-83.
22. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. A gynecologic oncology group study. Gynecol Oncol 1991;40:455-65.
23. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984;17:85-103.
24. Shumsky AG, Stuart GCE, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994;55:229-33.
25. Kaplan EW, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
26. Mantel N. Evaluation of the survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
27. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;34:187-220.
28. Hacker NF. Uterine cancer. In: Berek JS, Hacker NF, editors. Practical gynecologic oncology. 2nd ed. Baltimore (MD): Williams & Wilkins; 1994. p. 285-311.
29. Berchuck A, Anspach C, Evans AC, Soper JT, Rodriquez GC, Dodge R, et al. Postsurgical surveillance of patients with FIGO stage 1/11 endometrial adenocarcinoma. Gynecol Oncol 1995;59:20-4.
30. Podczaksi E, Kaminski P, Gurski K, MacNeill C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 1992;47:323-7.
31. Vavra N, Denison U, Kucera H, Barrada M, Kurz C, Salzer H, et al. Prognostic factors related to recurrent endometrial carcinoma following initial surgery. Acta Obstet Gynecol 1993;72:205-9.
32. Barnhill D, O'Connor D, Farley J, Teneriello M, Armstrong D, Park R. Clinical surveillance of gynecologic cancer patients. Gynecol Oncol 1992;46: 275-80.